Extended Data Fig. 8: Reserpine enhances CD8⁺ T cell-dependent anti-tumor immune response, related to Fig.6.

a, Growth curves of MC38 tumors at day 7-day 16 post-inoculation in Rag1^−/− mice that were injected intraperitoneally with vehicle or 1 mg/kg reserpine (every three days), starting at day 6 post-inoculation (n = 6 mice per group). b, Representative flow cytometry dot plots and corresponding frequencies (among CD45⁺ cells) of PMN-MDSCs in peripheral blood from C57BL/6 mice at day 16 post-inoculation with MC38 cells, treated with 10 mg/kg IgG isotype or 10 mg/kg Ly-6G antibody at day 5, 8, 12 and 15 post-inoculation (n = 3 biological replicates). c, Quantification of tumor burden in the proximal, middle and distal small intestine and colorectum in Apc^Min/+ mice at week 15, injected intraperitoneally with vehicle or 1 mg/kg reserpine, starting at week 8 (n = 6 mice per group). d, Representative hematoxylin and eosin staining in colorectal tumors from Apc^Min/+ mice as in (c). Scale bar, 50 μm. e, Kaplan-Meier survival curves of Apc^Min/+ mice injected intraperitoneally with vehicle or 1 mg/kg reserpine (every three days), starting at 8 weeks of age (n = 6 mice per group). f, Flow cytometry analysis of frequencies (among CD45⁺ cells) of CCR2⁺ PMN-MDSCs in colorectal tumors from Apc^Min/+ mice as in (c) (n = 6 biological replicates). g, Flow cytometry analysis of frequencies of CD8⁺ T cells among CD45⁺ cells, and GzmB⁺ cells gated on CD45⁺CD8⁺ T cells in colorectal tumors from Apc^Min/+ mice as in (c) (n = 6 biological replicates). h, Representative immunofluorescence staining for CD8α and GzmB in colorectal tumors from Apc^Min/+ mice as in (c). Results are representative of two or three independent experiments. All bars in graph represent mean ± s.e.m. (a-c, f-g) two-tailed unpaired student’s t test; (e) Log rank test. Ab, antibody.

Source data